Dr. Brinton is a Clinical Professor of Medicine (Cardiology) and an Adjunct Professor of Bioengineering at Stanford University. He is an attending interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the fellowship director for the Stanford Program in Biodesign since 2005 and also co-directs both the executive education program in innovation management and the Stanford graduate course series in biodesign innovation.
His responsibilities include lecturing on strategies for innovation as well as coaching and mentorship of the innovation fellows, graduate students, and executives. Dr. Brinton’s academic research focuses on the process of innovation for development of novel medical technologies. He specifically focuses on the integration of research and development for new technologies with the clinical strategy and pre-clinical evaluation. He has served as a clinical investigator for a number to studies of interventional-based therapies for chronic ischemia heart disease and heart failure.
Dr. Brinton completed his medicine, cardiology, and interventional training at Stanford University. He holds an MD from the Chicago Medical School and a BS in bioengineering from the University of California, San Diego. He is co-founder and board director for Shockwave Medical and BioParadox, Inc., which are both venture-backed medical device companies in the cardiovascular space. He also serves on the board of directors of Qool therapeutics and Infogard laboratories. Additonally, he serves on the advisory board of a number of early-stage medical device companies where he focuses on clinical development and strategy. Prior to medical school he was the Clinical Research Director for Pulse Metric, Inc., a medical device start-up company.